Company Profile
Simcere Pharmaceutical Group Limited, an investment holding company develops, manufactures, and sells pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
It develops Endostar, a recombinant human endostatin injection. Its portfolio also includes ENWEIDA, an envafolimab injection, Leruiping, a fully human monoclonal antibody targeting IL-4Ra, Zemprocitinib a highly selective JAK1 inhibitor, and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials.
It also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics. Its portfolio also includes Denlorlatinib, SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway, deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial
Sanbexin an injection new indication, Sanbexin a sublingual tablets, and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulatory T cells that is in Phase 2 clinical trials. It develops SIM0237, an anti-PD-L1 monoclonal antibody fused with IL-15/IL15RXa sushi protein.
Its portfolio also includes Enzeshu, a suvemcitug for injection, SIM0500, a humanized trispecific antibody that targets GPRC5D/BCMA/CD3, SIM0508, a small molecule inhibitor, SIM0505, a CDH6-targeting ADC molecule, SIM0686, an ADC drug targeting FGFR2b, SIM0609, a new antibody-drug conjugate targeting CDH17, SIM0610, a bispecific antibody-drug conjugate, SIM0532, an oral, non-covalent pan-RAS inhibitor, SIM0323, and SIM0811, a small-molecule plasminogen allosteric activator that are in Phase 1 clinical trial.
The company develops SIM0613. Its portfolio also includes SIM0709, SIM0689, SIM0688, SIM0518, SIM0616, SIM0611, SIM0815, SIM0712, SIM0725, SIM0708, SIM0721, and SIM0722 that are in pre-clinical stage.